EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune Checkpoint Inhibitor‐Induced Endocrine Dysfunction: Early Detection of Symptoms and Timely Intervention

Nadia Grace Obaed iD, Kadiyatu Fofana, Ahmad Matarneh, Sundus Sardar iD, Naman Trivedi, Nasrollah Ghahramani

Clinical Case Reports · 2026-04 · 14 (4)

DOI: 10.1002/ccr3.72528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Case Reports, online erschienen am 14.04.2026. Verfasst von Nadia Grace Obaed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine-Pediatrics Penn State Milton S. Hershey Medical Center Hershey USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICI) target immune regulatory pathways to enhance antitumor responses. Although these agents improve survival, they can cause immune‐related adverse events (irAEs). Hypophysitis is a recognized irAE—particularly with CTLA‐4 inhibitors—but this case is notable for occurring in an elderly patient receiving combination therapy and presenting with nonspecific symptoms that mimicked cancer‐related fatigue and treatment side effects. We report a 76‐year‐old woman on ICI therapy who developed intractable back pain, nausea, and severe hyponatremia, ultimately diagnosed with ICI‐induced hypophysitis. Her evaluation revealed multiple electrolyte abnormalities, secondary adrenal insufficiency, and pituitary enlargement on magnetic resonance imaging (MRI), necessitating urgent fluid resuscitation and corticosteroid replacement. As use of ICIs expands across malignancies, understanding the side effect profile and atypical or subtle presentations is essential in providing prompt diagnosis and treatment of sequelae that can mimic autoimmune diseases. It underscores diagnostic complexity in real‐world settings and the need for heightened awareness of adverse endocrine events, especially in older patients and those receiving sequential or combination regimens. Careful monitoring of irAEs allows for irAEs risk mitigation and improves patient tolerability in continuing ICI cancer treatment. Clinicians should maintain a high index of suspicion and implement appropriate monitoring protocols for early detection.

Schlagwörter

Stichwörter der Autor:innen

adrenal insufficiencyendocrine toxicityhypophysitisimmune checkpoint inhibitorsimmune‐related adverse events

Autor:innen und Institutionen

  • Department of Internal Medicine-Pediatrics Penn State Milton S. Hershey Medical Center Hershey USA.
  • Department of Medicine Penn State Milton S. Hershey Medical Center Hershey USA.
  • Department of Nephrology Penn State Milton S. Hershey Medical Center Hershey USA.

ORCID-Profile: Nadia Grace Obaed, Sundus Sardar

Zitieren

APA

Obaed, N. G., Fofana, K., Matarneh, A., Sardar, S., Trivedi, N., & Ghahramani, N. (2026). Immune Checkpoint Inhibitor‐Induced Endocrine Dysfunction: Early Detection of Symptoms and Timely Intervention. Clinical Case Reports, 14(4). https://doi.org/10.1002/ccr3.72528

Vancouver

Obaed NG, Fofana K, Matarneh A, Sardar S, Trivedi N, Ghahramani N. Immune Checkpoint Inhibitor‐Induced Endocrine Dysfunction: Early Detection of Symptoms and Timely Intervention. Clinical Case Reports. 2026;14(4). doi:10.1002/ccr3.72528

BibTeX
@article{Obaed2026,
  author = {Obaed, Nadia Grace and Fofana, Kadiyatu and Matarneh, Ahmad and Sardar, Sundus and Trivedi, Naman and Ghahramani, Nasrollah},
  title = {Immune Checkpoint Inhibitor‐Induced Endocrine Dysfunction: Early Detection of Symptoms and Timely Intervention},
  journal = {Clinical Case Reports},
  year = {2026},
  volume = {14},
  number = {4},
  doi = {10.1002/ccr3.72528}
}
Kostenlos starten →